We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Based on President Bush’s State of the Union address, the debate over how to improve the healthcare system comes down to the administration’s call for tax deductions and state grant programs versus Democrats’ plans to give the government the authority to negotiate Medicare prices.
Republican members of the House and Senate are proposing a federal commission to study entitlement spending, including Medicare and Medicaid, with an eye toward developing ways to lower the costs of these programs.
Rep. Rosa DeLauro (D-Conn.), the incoming chairwoman of the subcommittee with jurisdiction over the FDA’s budget, has a number of changes in mind for the agency, starting with an improved drug review system, the lawmaker says.
A bipartisan group of House and Senate lawmakers have reintroduced legislation from the last congressional session that would allow limited importation of prescription drugs.
A panel of drug industry representatives presented their views on the effects of reverse-payment deals before federal lawmakers at a Senate hearing called to consider proposed legislation that could stop the practice of paying generic drug companies to limit market competition.
Leading Senate Democrats believe that they are only a few votes away from having the support necessary to overcome a promised presidential veto of stem cell legislation and say that increasing public and political pressure will be enough to give them the necessary support.
Rep. Rosa DeLauro (D-Conn.), the incoming chairwoman of the subcommittee with jurisdiction over the FDA’s budget, has a number of changes in mind for the agency, starting with an improved drug review system, the lawmaker says.
Republican members of the House and Senate are proposing a federal commission to study entitlement spending, including Medicare and Medicaid, with an eye toward developing ways to lower the costs of these programs.
A panel of drug industry representatives presented their views on the effects of reverse payment deals before federal lawmakers at a Senate hearing called to consider proposed legislation that could stop the practice of paying generic drug companies to limit market competition.
The Democrats’ plan to give the federal government the authority to negotiate for lower Medicare prices has taken another step forward as the House passed H.R.4 Jan. 12 by a vote of 255–170.